Procalcitonin as a marker of medullary thyroid carcinoma

Cancela-Nieto, María G; Sánchez-Sobrino, Paula; Velo-García, Alba

doi:10.23736/s2724-6507.20.03229-0

Cited by 6 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from the calcitonin-producing parafollicular C cells of the thyroid [ 1 ]. In 75% of cases, MTC occurs sporadically, and in a familial form for the remaining 25%.…”

Section: Introductionmentioning

confidence: 99%

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer

Saronni

Gaudenzi

Dicitore

et al. 2022

Cancers

View full text Add to dashboard Cite

Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from parafollicular C cells of the thyroid gland. In this preclinical study, we tested three tyrosine-kinase inhibitors (TKIs): SU5402, a selective inhibitor of fibroblast growth factor receptor (FGFR)-1 and vascular endothelial growth factor receptor (VEGFR)-2; sulfatinib, an inhibitor of FGFR-1 and VEGFR-1, -2, -3; and SPP86, a RET-specific inhibitor. The effects of these compounds were evaluated in vitro in two human MTC cell lines (TT and MZ-CRC-1), and in vivo using xenografts of MTC cells in zebrafish embryos. SU5402, sulfatinib and SPP86 decreased cell viability. Sulfatinib and SPP86 significantly induced apoptosis in both cell lines. Sulfatinib and SPP86 inhibited the migration of TT and MZCRC-1 cells, while SU5402 was able to inhibit migration only in TT cells. In vivo we observed a significant reduction in TT cell-induced angiogenesis in zebrafish embryos after incubation with sulfatinib and SPP86. In conclusion, sulfatinib and SPP86 displayed a relevant antitumor activity both in vitro and in vivo. Moreover, this work suggests the potential utility of targeting FGFR and VEGFR signaling pathways as an alternative therapy for MTC.

show abstract

Section: Introductionmentioning

confidence: 99%